Kymera Therapeutics, Inc.

NASDAQ:KYMR

Biotechnology

Healthcare
$119.39 +1.67%

+$1.50 today

Market cap
$10.19B
Beta
2.03
P/E (TTM)
-28.3
EPS (TTM)
-$3.23
52W Low $36.65High $103.00

Volume 0.72M

Average 0.58M

Income Statement

Follow revenue through to earnings.

Revenue

$39.20M

FY 2025 · Annual

-16.7% YoY

Operating Income

-$349.40M

FY 2025 · Annual

Net Income

-$311.40M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.83M46.83M78.59M47.07M39.2M
Cost of Revenue00000
Gross Profit72.83M46.83M78.59M47.07M39.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development137.02M164.25M189.08M240.25M316.6M
Selling, General & Admin36.35M43.83M55.04M63.53M68.2M
Operating Expenses173.36M208.08M244.12M308.71M388.6M
Depreciation & Amortization2.4M2.98M3.57M7.37M8.31M
EBITDA(97.65M)(151.66M)(143.2M)(216.24M)(303.06M)
EBITDA Margin-134.1%-323.9%-182.2%-459.4%-773.1%
Operating Income(100.53M)(161.26M)(165.53M)(261.64M)(349.4M)
Operating Margin-138.0%-344.4%-210.6%-555.8%-891.3%
Interest Income488K6.62M18.76M38.03M38.03M
Interest Expense175K176K196K249K249K
Other Income / Expenses313K6.45M18.57M37.78M37.78M
Income Before Tax(100.22M)(154.81M)(146.96M)(223.86M)(311.62M)
Pre-Tax Margin-137.6%-330.6%-187.0%-475.6%-795.0%
Income Tax Expense00000
Net Income(100.22M)(154.81M)(146.96M)(223.86M)(311.4M)
Net Margin-137.6%-330.6%-187.0%-475.6%-794.4%
EPS (Basic)(2.09)(2.87)(2.52)(2.98)(3.69)
EPS (Diluted)(2.09)(2.87)(2.52)(2.98)(3.69)
Weighted Avg Shares47.99M53.93M58.37M75.04M84.39M
Weighted Avg Shares (Diluted)47.99M53.93M58.37M75.04M84.39M

KYMR Earnings Waterfall · TTM

NASDAQ:KYMR · Revenue to Net Income

Key Ratios

EPS$-3.25
Gross Margin95.7%
Net Margin-1577.9%
P/E Ratio-27.6
P/S Ratio1123.3

Analysis

$105.0M of revenue converted into -$299.6M of net income for the selected period. Gross margin is 95.7% and net margin is -1577.9%, showing how much revenue survives after costs and taxes. EPS is $-3.25, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportOct 29, 2026
10-QQuarterly reportOct 29, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
4Statement of changes in beneficial ownershipOct 1, 2026
SC 13G/ASC 13G/A filingSep 8, 2026

How much revenue does KYMR generate?

Kymera Therapeutics, Inc. (KYMR) reported $39.20M of revenue in fiscal 2025.

Is KYMR profitable?

Kymera Therapeutics, Inc. (KYMR) reported -$311.40M of net income, with a net margin of -794.4%.